Worldpay From FIS Opens New Growth Opportunities with United Arab Emirates Expansion

Worldpay From FIS Opens New Growth Opportunities with United Arab Emirates Expansion

Key facts

  • Worldpay from FIS continues to drive global e-commerce with new domestic acquiring capability in the UAE.
  • Expansion is part of business' plans to expand its merchant acquiring presence in key markets.

Continuing to build its footprint as a leading global acquirer, global financial technology leader FIS ® (NYSE: FIS) has announced today its Worldpay merchant business will be expanding its payment processing capabilities into the United Arab Emirates (UAE) this year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005030/en/

Worldpay has secured a category II payment services license that allows for card acquiring and disbursements. This new domestic license in the UAE will enable the company to offer its world-class payment services to both local companies with global ambitions, and rapidly growing enterprises looking to expand in the market. This comes on the back of its successful expansion into South Korea in 2022 .

Our newest version of The Global Payments Report shows the e-commerce market in the UAE is projected to reach US$43 billion by 2026, with credit cards driving this growth, accounting for 41% of e-commerce transaction value in 2022. This makes it even more important for merchants to select the right payment partner for their business.

"The UAE presents new growth opportunities for global businesses and it's an exciting time to be entering the market," said Gabriel de Montessus, Head of Global Enterprise Merchant Solutions, FIS. "Our new domestic acquiring capability in the UAE will ensure seamless integration into the country for global merchants, while local businesses will benefit from our leading geographic footprint, enabling them to expand globally. Our expertise in payments helps us understand how local consumers prefer to pay, as well as the trends that merchants need to get ahead of to optimize their performance as they enter new markets and accelerate global commerce."

Merchants doing business in the UAE will be able to take advantage of Worldpay's advanced acquiring capabilities, which will be able to connect them to authorization, clearing and payments settlement, dispute management software and data insights. Merchants will also benefit from a seamless payments experience through a single point of integration—helping to increase acceptance, improve customer experience, and reduce fraud. Supporting this new market is a proof point of Worldpay's growth strategy to enhance its merchant acquiring presence in additional markets and expand its global capability.

About FIS

FIS is a leading provider of technology solutions for financial institutions and businesses of all sizes and across any industry globally. We enable the movement of commerce by unlocking the financial technology that powers the world's economy. Our employees are dedicated to advancing the way the world pays, banks and invests through our trusted innovation, system performance and flexible architecture. We help our clients use technology in innovative ways to solve business-critical challenges and deliver superior experiences for their customers. Headquartered in Jacksonville, Florida, FIS is a member of the Fortune 500 ® and the Standard & Poor's 500 ® Index. To learn more, visit www.fisglobal.com . Follow FIS on Facebook , LinkedIn and Twitter ( @FISGlobal ).

Kim Snider, 904.438.6278
Senior Vice President
FIS Global Marketing and Communications
kim.snider@fisglobal.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Apple scores record 72 Emmy Award nominations and sweeps across top categories including Outstanding Limited series for "Lessons in Chemistry," Outstanding Drama for "The Morning Show" and "Slow Horses" and Outstanding Comedy for "Palm Royale"

Apple scores record 72 Emmy Award nominations and sweeps across top categories including Outstanding Limited series for "Lessons in Chemistry," Outstanding Drama for "The Morning Show" and "Slow Horses" and Outstanding Comedy for "Palm Royale"

With best-ever Emmy showing, Apple TV+ lands nominations across 16 Apple Originals including "Lessons in Chemistry," "The Morning Show," "Slow Horses," "Palm Royale," "Loot," "Hijack," "STEVE! (martin) a documentary in 2 pieces," "Girls State," "The Reluctant Traveler With Eugene Levy," "Masters of the Air," "Silo," "Physical," "Hannah Waddingham: Home for Christmas," "The New Look," "Sugar" and more

"The Morning Show" lands first-ever nomination for Best Drama and leads with the most performance nominations for a drama series, including Best Actress in a Drama for stars and executive producers Jennifer Aniston and Reese Witherspoon

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal (GI) infection diagnosis.

The QIAstat-Dx Gastrointestinal Panel 2 takes about an hour to simultaneously look for up to 16 clinically relevant bacterial, viral and parasitic pathogens that cause most GI infections. Acute infectious gastroenteritis is a common reason for hospitalizations and outpatient physician visits in the U.S., with an estimated 180 million cases per year. [1]

The panel leverages QIAstat-Dx's ability to quickly multiply many genetic targets using real-time PCR technology in the same reaction – an important advance compared to traditional microbiological testing, which often requires samples to be incubated for at least 24 hours and up to 10 days of specimen collection. Software interprets signals from the reaction and provides positive or negative results for each pathogen. QIAstat-Dx additionally provides easy-to-view cycle threshold (Ct) values and amplification curves that can offer additional insights not available with end-point PCR or other techniques.

"The QIAstat-Dx Gastrointestinal Panel 2 allows medical professionals to identify which GI pathogen they are dealing with quickly," said Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. "This is QIAGEN's answer to two major problems in treating GI infections: diagnosis of overlapping symptoms and laborious testing methods."

"It can be very difficult to clinically distinguish between viral, bacterial and parasitic causes of GI illness. We can easily set up and get a full panel of results back faster than culture and microscopy, and access to Ct values for each detected pathogen can provide valuable information when interpreting when interpreting multiple pathogen detections," added Romney Humphries, Ph.D., professor of Pathology, Microbiology, and Immunology and division director for Laboratory Medicine at Vanderbilt University Medical Center in the U.S. about the clinical utility of QIAstat-Dx.

The new panel expands QIAGEN's U.S. menu for syndromic testing, building on the use of the QIAstat-Dx Respiratory Panel Plus that can identify 21 pathogens causing respiratory infections from viral and bacterial pathogens. Both Panels are available as cost-efficient, single-use cartridges that slot easily into the QIAstat-Dx Analyzer 1.0. As they contain all reagents, set up takes less than a minute and requires no precision pipetting.

The U.S. launch supports healthcare providers with diagnosing and treating patients quickly and accurately. They will be able to quickly isolate those at risk of transmitting infections and identify negative cases sooner, reducing the burden of unnecessary testing and treatment costs on the healthcare system and patients. Syndromic tests have also been shown to improve the detection of co-infections, reducing the need for additional testing like endoscopies. By providing fast results, syndromic testing enables healthcare providers to make informed decisions and discontinue empiric antibiotic treatment when viral pathogens are detected, reducing overall antibiotic usage and supporting the goal of responsible antimicrobial stewardship.

Syndromic testing with cloud-based connectivity and epidemiological insights

QIAstat-Dx solutions and syndromic tests to support diagnosing diseases are available in more than 100 countries worldwide, including the U.S. and many across Europe. More than 4,000 cumulative systems were installed worldwide at the end of 2023. Hospitals, laboratories and clinics value the QIAstat-Dx range as an easy-to-use automated solution for the reliable detection of various pathogens.

QIAstat-Dx is available in two formats: The QIAstat-Dx version that brings together up to four Analytical Modules into one integrated system, and the QIAstat-Dx Rise higher-capacity version that provides comprehensive testing for up to 160 tests per day using eight Analytical Modules. QIAstat-Dx Rise is available with CE-IVD marking in Europe and other countries that accept this marking.

With a QIAstat-Dx Connectivity plan, QIAstat-Dx connects to the QIAsphere cloud-based platform that provides remote monitoring of the instruments and test status, allowing customers to receive push notifications on their personal devices. It can monitor an unlimited number of instruments across different hospitals or satellite labs, reducing system downtime and enabling fast and accurate syndromic testing. Connectivity is achieved through the Qbase hub, which can be connected to QIAstat-Dx in minimal time through hospitals' LAN or Wi-Fi network, ensuring sensitive patient data remains within the hospital network.

QIAsphere also allows users to view and export reports on real-time local, regional and global epidemiology data through QIAsphere Insights to support epidemiological surveillance . Further, with the recent release of a medical reference app for QIAstat-Dx users, the Pathogen Guide , QIAstat-Dx is poised as a leader in digital diagnostic technology for customers around the world.

Learn more about QIAstat-Dx and the Gastrointestinal Panel 2 at https://www.qiagen.com/applications/syndromic-testing/benefits/gastrointestinal-care

About QIAGEN

Qiagen N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com .

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: Qiagen N.V.
Category: Corporate

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Best-Selling Cessna Citation Latitude and Flagship Citation Longitude to Offer New Advanced Avionics Features

Best-Selling Cessna Citation Latitude and Flagship Citation Longitude to Offer New Advanced Avionics Features

Textron Aviation today announced advanced Garmin G5000 avionics enhancements coming to the best-selling mid-size business jet, the Cessna Citation Latitude, and the flagship of the Citation family of jets, the Citation Longitude. Textron Aviation's investments in the popular business jets, based on customer feedback, will offer greater performance and improved user experience to pilots in the new Latitude jets beginning in 2025 and the new Longitude jets in 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527032307/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Element79 Gold: Ongoing Commitment to Community Empowerment

Element79 Gold: Ongoing Commitment to Community Empowerment

(TheNewswire)

Element79 Gold Corp.

Chachas, Arequipa, Peru

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Gravity Survey Results Identify High Impact Near Deposit Massive Sulphide Exploration Targets at its Lagoa Salgada VMS Project, in Portugal

Gravity Survey Results Identify High Impact Near Deposit Massive Sulphide Exploration Targets at its Lagoa Salgada VMS Project, in Portugal

  • New High-Resolution gravity survey suggests potential to rapidly expand Massive Sulphide Mineralization at current Venda Nova North and South Deposits
  • Multiple additional gravity anomalies identified to potentially add to the Massive Sulphide Ore Bodies near Venda Nova
  • EDM's Option to gain a 15% interest in the Project extended to September 30, 2024 due to upcoming elections and government change

Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASDRF)(FRA:2D9) ("Ascendant" or the "Company") is pleased to announce the results of its recent high-resolution gravity survey completed over the Venda Nova North and South Deposits at its Lagoa Salgada VMS Project, in Portugal

Key Highlights

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Real Matters Reports Second Quarter Financial Results

(all amounts are expressed in millions of U.S. dollars, excluding per share amounts and unless otherwise stated)

Real Matters Inc. (TSX: REAL) ("Real Matters" or the "Company"), a leading network management services platform for the mortgage and insurance industries, today announced its financial results for the second quarter ended March 31, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters Announces Changes to its Board of Directors

Real Matters Inc. ("Real Matters" or the "Company"), a leading network management services provider for the mortgage lending and insurance industries, today announced that Lisa Melchior will be stepping down after serving on the Real Matters Board since 2017. The Company also announced the appointment of Kay Brekken to its Board of Directors. Ms. Brekken will succeed Ms. Melchior as a member of the Compensation, Nomination and Governance Committee. The changes are effective May 7, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507719548/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Announce Second Quarter Fiscal 2024 Financial Results on May 7, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will announce its second quarter fiscal 2024 financial results via news release on Tuesday, May 7, 2024, before market open.

Conference Call and Webcast

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters Reports First Quarter Financial Results

(all amounts are expressed in millions of U.S. dollars, excluding per share amounts and unless otherwise stated)

Real Matters Inc. (TSX: REAL) ("Real Matters" or the "Company"), a leading network management services platform for the mortgage and insurance industries, today announced its financial results for the first quarter ended December 31, 2023.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Hold Virtual Annual General Meeting on February 8, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will be holding its Annual General Meeting (the "Meeting") on Thursday, February 8, 2024 at 10:00 a.m. (Eastern Standard Time). The Meeting will be conducted online only, via audio webcast at: www.virtualshareholdermeeting.com/realmatters2024 .

Registered and non-registered shareholders entitled to vote at the Meeting may vote by proxy in advance of the Meeting. However, only registered shareholders and duly appointed proxyholders (including non-registered shareholders who have duly appointed themselves as proxyholder) will be entitled to vote at the Meeting during the live audio webcast. Non-registered shareholders who have not duly appointed themselves as proxyholders will be able to attend the Meeting and ask questions, but will not be able to vote. Guests will be able to attend the Meeting but will not be able to submit questions, vote their shares (if any) or otherwise participate in the Meeting. Please note that registered shareholders will need the 16-digit control number indicated on the form of proxy accompanying their Notice of Meeting to log on to the Meeting as a "Shareholder". Duly appointed proxyholders will need the Appointee Name and 8-character Appointee Identification Number to log on to the Meeting as a "Proxyholder / Appointee". Otherwise, shareholders or duly appointed proxyholders, as applicable, will have to log on as "Guests". Please refer to the Company's Management Information Circular in the Investor Relations section of our website for additional details on how to log on to the Meeting.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Real Matters to Announce First Quarter Fiscal 2024 Financial Results on February 1, 2024

Real Matters Inc. ("Real Matters"), a leading network management services provider for the mortgage lending and insurance industries, will announce its first quarter fiscal 2024 financial results via news release on Thursday, February 1, 2024, before market open.

Conference Call and Webcast

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×